Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.